Investors & Media

What’s new.

Press releases

Press releases.

May 15th 2025

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 5th 2025

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

April 29th 2025

Immutep Quarterly Activities Report Q3 FY25

more

Investor updates

Investor updates.

April 23rd 2025

Investor Update - April 2025

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

more

Analyst reports

Analyst reports.

May 15th 2025

Baird - New IST Data for Triple Combo Further Supportive of Potential in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

May 15th 2025

CLSA - Insightful readout; Outperform, A$0.28 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

Wilsons - INSIGHT-003 | Even in the arctic tumours; Maintain Overweight, A$1.05 PT(Analysts: Dr Shane Storey and Dr Lisa Worley)

more